The study of molecular interactions at the cellular level has led to significant advancements in how we understand chemokine signaling. Among the various receptors of interest, CCR2 (also known as CD192) has emerged as a focal point for researchers exploring the CCL2-CCR2 signaling axi Inhibition of the CCL2 receptor, CCR2, enhances tumor s. As someone deeply interested in the nuances of peptide science, I have spent considerable time reviewing the literature surrounding CCR2 targeting peptides and their roles in experimental models.
Understanding the CCR2 Receptor
CCR2 is a 38 kDa, 7-TM (seven-transmembrane) chemokine receptor that belongs to the beta-chemokine receptor family. It primarily acts as a ligand for C-C chemokine receptor CCR2, maintaining a high affinity for chemokines such as CCL2 (MCP-1), CCL7, and CCL13. Because it is a receptor for the CCL2, CCL7 and CCL13 chemokines, it plays a critical role in mediating the chemotactic response of various immune cells, including monocytes and macrophages Next-IO™ Anti-CCL2/CCR2 Axis Targeted Therapeutic .
In the context of targeting specific biological path CCR2refers to a member of the beta chemokine receptor family, specifically one of the CC chemokine receptors, which have 11 distinct subtypes.Read more ways, the scientific community often utilizes specialized tools to isolate or inhibit these interactions. This is where the development of synthetic peptides has become indispensable.
Types of CCR2-Related Peptides
My experience with these products reveals a wide range of utility, from basic research to complex diagnostic applications. Here is a breakdown of the common categories:
* Antibody Blocking Peptides: A CCR2 antibody blocking peptide (such as NBP1-78169PEP) is a synthetic peptide corresponding to the N-terminal region of the CCR2 protein, usually spanning specif Molecular insights into ligand recognition and activation of ic amino acids like 30-60. These are essential for verifying antibody specificity, as they are peptides that bind specifically to the target antibody to prevent non-specific binding.
* Pepducins and Inhibitors: Researchers often investigate the CCR2-selective pepducin PP101 for its ability to modulate receptor signaling. Unlike large antibodies, these smaller molecules offer unique pharmacokinetic profiles in experimental settings.
* Diagnostic Tools: Innovation in imaging has led to tracers like DOTA-ECL1i, which serves as a PET tracer that targets CCR2 expression. By conjugating these peptides to imaging agents, researchers can visualize the density of these receptors in various environments.
* Decoy Proteins and Traps: The use of a recombinant sulfated CCR2 peptide trap has shown promise in modulating localized signaling. These traps function by sequestering ligands before they can bind to the actual receptor.
The Role of the CCL2/CCR2 Axis
The strategies to target CCL2/CCR2 axis mechanics are largely driven by the observation that this pathway is involved in tumorigenesis and tumor development. When the axis is hyper-activated, it can drive the recruitment of myeloid cells into the tumor microenvironment. Consequently, many studies focus on how effectively one can disrupt this communication.
For instance, the CCR2 blocking peptide Inhibition of inflammatory CCR2 signaling promotes aged is frequently used in laboratory protocols to ensure that by SA Jung·2021·Cited by 5—Here, we generated arecombinant sulfated CCR2 peptide trap(mCCR2-S2) and investigated its effects on retinal degeneration in mice.Read more observed effects are indeed mediated through the specific receptor-ligand interaction. By validating these pathways, scientists can better understand the underlying biology of Ccr2 without the interference of Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy off-target effects.
Practical Considerations for Researchers
When sourcing these materials, it is vital to adhere to rigorous laboratory standards. Many of these peptides are highly sensitive to temperature. For example, a standard CCR2 blocking peptide should typically be stored at -80°C to maintain structural integrity, as frequent freeze-thaw cycles can degrade the peptide's ability to bind to its intended target.
Furthermore, when discussing therapeutic candidates like Plozalizumab (MLN-1202), it is clear that the field is moving toward high-precision tools. While monoclonal antibodies are effective, the flexibility provided by smaller peptides allows for more specialized research into receptor domains, such as the ECL1i loop, which specifically binds to the receptor.
Conclusion
The exploration CCR2 Antibody Blocking Peptide (NBP1-48338PEP) of CCR2 target A New Target for Cancer Immunotherapy-CCR2 ing peptides continues to provide deep insights into cellular signaling. Whether through the use of blocking agents for validation or the development of novel PET tracers, the ability to selectively interact with CCR2 remains a cornerstone of modern biochemical investigation. By focusing on the structural and functional properties of these molecules, researchers can continue to map the complex pathways that govern immune cell recruitment and tissue-level responses.